Prescription Dermatology & Eye Care Products
Specific dermatological and ophthalmological conditions
Approved/CommercialRelaunched (2024)
Key Facts
Indication
Specific dermatological and ophthalmological conditions
Phase
Approved/Commercial
Status
Relaunched (2024)
Company
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals leverages its proprietary Microcyn® Technology, the world's first patented and shelf-stable hypochlorous acid formulation, to address a broad range of infection control and skin health needs. With a global presence in over 50 countries, a portfolio backed by numerous patents and regulatory approvals, and a product line spanning wound care, dermatology, and consumer health, the company is positioned as a leader in HOCl-based solutions. Its strategic direction includes expanding direct offerings in dermatology and eye care, while pursuing wholesale, partnership, and distributor opportunities to grow its market reach.
View full company profile